Article Sidebar
Published:
Feb 5, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of cisplatin and fluorouracil chemotherapy plus Jianpi Yiqi formula in the treatment of advanced gastric cancer
Abstract
Purpose: To investigate the efficacy of cisplatin and fluorouracil chemotherapy in combination with the Jianpi Yiqi formula in the treatment of advanced gastric cancer.
Methods: A total of 64 patients with advanced gastric cancer admitted and treated at Xianyang Central Hospital from April 2019 to October 2021 were recruited and assigned equally to chemotherapy group and combination group according to the time of admission. Chemotherapy group received cisplatin and fluorouracil, while the combination group received the Jianpi Yiqi formula based on the treatment given to the chemotherapy group. Some clinical indices were evaluated in the patients.
Results: Intervention in the combination group was associated with a higher total effectiveness when compared with chemotherapy group (p < 0.05). Cisplatin and fluorouracil plus Jianpi Yiqi formula resulted in significantly higher European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) score than cisplatin with fluorouracil (p < 0.05). Furthermore, cisplatin and fluorouracil plus Jianpi Yiqi formula led to considerably higher Karnofsky Performance Scale (KPS) scores versus cisplatin with fluorouracil (p < 0.05).
Conclusion: In the treatment of advanced gastric cancer, cisplatin-fluorouracil chemotherapy in conjunction with the Jianpi Yiqi formula produces remarkable efficacy. This strategy increases lesion dissolution rates, improves the quality of life and behavioral status of patients, and reduces adverse reactions, resulting in prolonged patients' progression survival (PFS) and overall survival (OS) levels.
